Asami Ito
Overview
Explore the profile of Asami Ito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujiwara Y, Kuroda H, Abe T, Nagasawa T, Nakaya I, Ito A, et al.
Sci Rep
. 2025 Feb;
15(1):4547.
PMID: 39915518
We aimed to elucidate the value of ultrasound-based biomarkers for predicting the major life-threatening events in metabolic dysfunction-associated steatotic liver disease (MASLD). We established a prospective cohort of 279 patients...
2.
Kuroda H, Abe T, Kamiyama N, Oguri T, Ito A, Nakaya I, et al.
J Gastroenterol
. 2024 Dec;
60(2):260.
PMID: 39673559
No abstract available.
3.
Kuroda H, Abe T, Kamiyama N, Oguri T, Ito A, Nakaya I, et al.
J Gastroenterol
. 2024 Oct;
60(2):187-196.
PMID: 39470783
Background: Subharmonic-aided pressure estimation (SHAPE) is a technique for determining changes in ambient pressure. We aimed to analyze a novel SHAPE integrated into ultrasound diagnostic equipment to predict patients with...
4.
Fujiwara Y, Kuroda H, Abe T, Kakisaka K, Nakaya I, Ito A, et al.
Drugs Real World Outcomes
. 2024 Oct;
11(4):701-710.
PMID: 39384684
Background And Objective: Durvalumab plus tremelimumab (Durva/Treme) has recently been approved as a first-line or later-line treatment for patients with unresectable hepatocellular carcinoma (u-HCC) in Japan. We assessed the real-world...
5.
Abe H, Endo K, Kuroda H, Oikawa T, Abe T, Ito A, et al.
Clin J Gastroenterol
. 2024 Jan;
17(2):307-310.
PMID: 38185741
The HIMALAYA trial is the first chemotherapeutic trial to demonstrate the efficacy of combined immune checkpoint inhibitors (ICIs) for unresectable hepatocellular carcinoma (u-HCC). The STRIDE regimen used in this trial...
6.
Kishimoto K, Kakisaka K, Abe T, Ito A, Yusa K, Suzuki A, et al.
Intern Med
. 2023 Nov;
63(14):2011-2014.
PMID: 37981301
Prothrombin time (PT) is a key parameter for assessing the severity of liver disease. We present the case of a 37-year-old woman with severe acute liver injury due to autoimmune...
7.
Yoshida Y, Ito A, Eto H, Suzuki A, Abe T, Endo K, et al.
Hepatol Res
. 2023 Aug;
54(1):24-31.
PMID: 37635642
Aim: Hepatitis E virus (HEV) causes subclinical or acute self-limiting hepatitis. We surveyed the current seroprevalence and incidence of HEV infection among the general population in Iwate Prefecture, Japan, where...
8.
Yokoyama K, Kaneko T, Ieki Y, Ito A, Kawamoto E, Suzuki K, et al.
Cureus
. 2023 Mar;
15(2):e35233.
PMID: 36968897
Background: Positive end-expiratory pressure (PEEP), especially continuous high PEEP, is thought to be a risk factor for worsening renal function (WRF) due to impaired venous return and the development of...
9.
Oishi M, Tanaka K, Ishihara K, Iino K, Ito A, Yokoyama Y
J Matern Fetal Neonatal Med
. 2023 Mar;
36(1):2183757.
PMID: 36863711
Objective: Women with a history of hypertensive disorders of pregnancy (HDP), especially those with gestational hypertension and preeclampsia, are more likely to develop hypertension, cerebrovascular disease, ischemic heart disease, diabetes...
10.
Ikejiri K, Goto H, Usui M, Nakayama Y, Sugioka K, Ito A, et al.
Medicine (Baltimore)
. 2022 Nov;
101(45):e31755.
PMID: 36397415
Rationale: Septic pulmonary embolism (SPE) and subsequent pneumothorax are rare but serious conditions. We report a case of SPE and pneumothorax caused by central venous port (CV port) infection. Patient...